NVO
Novo Nordisk A/S
NVO has a slight edge over RXST overall, supported by stronger fundamentals and lower modeled downside.
RXST
RxSight, Inc.
RXST offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RXST Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Strong | |
| Strong |
RXST's cash flow and balance sheet are currently strong, but its revenue and profitability are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
RXST PE Valuation
RXST has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
RXST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
RXST has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over RXST on earnings quality, reporting a profit while its opponent remains loss making.
RXST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.28 | -$0.41 |
| Q2 2026 | -$1.13 | -$0.34 |
| Q1 2026 | -$1.13 | -$0.47 |
| Q4 2025 | -$0.95 | -$0.24 |
| Q3 2025 | -$0.87 | -$0.06 |
| Q2 2025 | -$0.79 | +$0.21 |
| Q1 2025 | -$0.66 | +$0.58 |
| Q4 2024 | -$0.71 | +$0.70 |
RXST is still losing money, but far less than before: $1.28 per share over the past year, against $3.19 at its worst in late 2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over RXST on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over RXST on profitability, with a higher operating margin.
RXST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.6M | -19% |
| Q2 2026 | $33.7M | +0.3% |
| Q1 2026 | $30.9M | -18% |
| Q4 2025 | $32.6M | -19% |
| Q3 2025 | $30.3M | -14% |
| Q2 2025 | $33.6M | -3.6% |
| Q1 2025 | $37.9M | +28% |
| Q4 2024 | $40.2M | +41% |
RXST's revenue has slid since its 2024 peak: $25M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -75% | -35 points |
| Q2 2026 | -41% | +0.8 points |
| Q1 2026 | -58% | -30 points |
| Q4 2025 | -35% | -13 points |
| Q3 2025 | -40% | -14 points |
| Q2 2025 | -42% | -18 points |
| Q1 2025 | -28% | +8 points |
| Q4 2024 | -21% | +17 points |
RXST's operating margin was −75% last quarter, down 35 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over RXST on cash flow, with more consistent year-over-year improvement.
RXST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44M | +$45.8M |
| Q2 2026 | -$11.5M | -$5.6M |
| Q1 2026 | -$11.7M | -$2.2M |
| Q4 2025 | -$2.3M | +$2.9M |
| Q3 2025 | -$1.8M | -$1.3M |
| Q2 2025 | -$5.9M | -$363K |
| Q1 2025 | -$9.4M | +$1.9M |
| Q4 2024 | -$5.1M | +$4.8M |
RXST's free cash flow has turned positive after six years mostly in the red: $19M over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over RXST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
RXST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +215K shares |
| 1 year | +1.8% | +740K shares |
| 3 years | +17% | +6M shares |
| 5 years | +901% | +37.5M shares |
| Available history | +119% | +22.6M shares |
RXST has 42M diluted shares, up 1.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
RXST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 0.3x | Very low |
| Q4 2020 | 0.5x | Very low |
RXST's net debt is less than a year of its operating earnings (EBITDA).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
RXST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.0 | Neutral |
| Stochastic | 22.2 | Neutral |
RXST's weekly RSI is 47 (neutral) and its Stochastic is 22 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RXST PE vs Healthcare Sector
RXST has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
RXST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.81 | 12% above |
| 20 week MA | $5.49 | 2% below |
| 50 week MA | $6.88 | 22% below |
| 100 week MA | $11.9 | 55% below |
| 200 week MA | $24.9 | 78% below |
RXST has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 78% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over RXST on returns for 2026, with the stronger performance.
RXST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.0 | $10.6 | -34% |
| 2022 | $10.6 | $11.9 | +12% |
| 2023 | $11.9 | $40.3 | +239% |
| 2024 | $40.3 | $34.2 | -15% |
| 2025 | $34.2 | $10.9 | -68% |
| 2026 YTD | $10.9 | $5.38 | -51% |
RXST's yearly returns have swung widely, from +239% in 2023 to −68% in 2025. It's down 51% so far in 2026.